SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Northwest Biotherapeutics Inc.
NWBO 0.251-0.6%9:48 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: John McCarthy8/21/2006 11:48:21 PM
   of 760
 
Outcome and prognostic factors in cerebellar glioblastoma multiforme in adults:

A retrospective study from the Rare Cancer Network.Weber DC, Miller RC, Villa S, Hanssens P, Baumert BG, Castadot P, Varlet P, Abacioglu U, Igdem S, Szutowicz E, Nishioka H, Hofer S, Rutz HP, Ozsahin M, Taghian A, Mirimanoff RO.
University Hospital of Geneva, Geneva, Switzerland; Paul Scherrer Institute, Villigen, Switzerland.

Purpose:
The aim of this study was to assess the outcome in patients with cerebellar glioblastoma (GBM) treated in 15 institutions of the Rare Cancer Network.

Methods and Materials:
Data from a series of 45 adult patients with cerebellar GBM were collected in a retrospective multicenter study.

Median age was 50.3 years.

Brainstem invasion was observed in 9 (20%) patients.

Radiotherapy (RT) was administered to 36 patients (with concomitant chemotherapy, 7 patients).

Adjuvant chemotherapy after RT was administered in 8 patients.

Median RT dose was 59.4 Gy. Median follow-up was 7.2 months (range, 3.4-39.0).

Results:

The 1-year
and 2-year actuarial overall survival rate
was 37.8%
and 14.7%, respectively,

and was significantly influenced by

salvage treatment (p = 0.048),
tumor volume (p = 0.044),
extent of neurosurgical resection (p = 0.019),
brainstem invasion (p = 0.0013),
additional treatment after surgery (p < 0.001),
and completion of the initial treatment (p < 0.001) on univariate analysis.

All patients experienced local progression:

8 and 22 had progression with and without a distant failure, respectively.

The 1-
and 2-year actuarial progression free survival

was 25% and 10.7%, respectively,

and was significantly influenced by

brainstem invasion (p = 0.002),
additional treatment after surgery (p = 0.0016),
and completion of the initial treatment (p < 0.001).

On multivariate analysis,

survival was negatively influenced by
the extent of surgery (p = 0.03)
and brainstem invasion (p = 0.02).

Conclusions:
In this multicenter retrospective study, the observed pattern of failure was local in all cases, but approximately 1 patient of 4 presented with an extracerebellar component.

Brainstem invasion was observed in a substantial number of patients and was an adverse prognostic factor.

PMID: 16814953 [PubMed - in process]

ncbi.nlm.nih.gov
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext